For the Inventor, By the Inventor

Enter assignee name

Zurich, Switzerland

Novo Nordisk Healthcare Ag

USPTO Granted Patents = 88

CIPO Patents = 8

EPO Patents = 69

Trademarks = 52

Forward Citations = 608

Loading Chart...

Loading Chart...

203 inventors (with patents filed for the assignee):

Michael Bech Jensen (11 out of 11 patents)

Ole Hvilsted Olsen (10 out of 43 patents)

Egon Persson (10 out of 14 patents)

4. Janus Krarup (8 out of 8 patents)

5. Birthe Lykkegaard Hansen (8 out of 8 patents)

6. Troels Kornfelt (7 out of 8 patents)

7. David R Lancia, Jr (6 out of 112 patents)

8. Gary Gustafson (6 out of 44 patents)

9. Neal Green (6 out of 21 patents)

10. Nils Langeland Johansen (6 out of 19 patents)

11. David James Richard (6 out of 32 patents)

12. Carsten Behrens (6 out of 20 patents)

13. Anna M Ericsson (6 out of 58 patents)

14. Zhongguo Wang (5 out of 57 patents)

15. Allan Christian Shaw (5 out of 5 patents)

Core Competencies:

Pyruvate Kinase R

Sickle Cell Disease

Coagulation Factor VII

Protein Conjugates

Growth Hormones

Polypeptide Modification

Protein Purification

Transglutaminase Catalyzed Reaction

Blood Coagulation Factors

Therapeutic Proteins

Hydrophobic Interaction Chromatography

O-linked Glycoforms

88 patents: Sort by Forward Citations

1. 12161634 - Pyruvate kinase R (PKR) activating compositions (2024-12-10),

2. 12128035 - Activating pyruvate kinase R (2024-10-29),

3. 12122778 - Activating pyruvate kinase R (2024-10-22),

4. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2024-08-27),

5. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-08-06),

6. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-05-14),

7. 11844787 - Activating pyruvate kinase R (2023-12-19),

8. 11219690 - Method for thioether conjugation of proteins (2022-01-11),

9. 11135275 - Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets (2021-10-05),

10. 11045523 - Formulation of growth hormone albumin-binder conjugate (2021-06-29),

11. 10851364 - Method of controlling a polypeptide modification reaction (2020-12-01),

12. 10844110 - O-linked glycoforms of polypeptides and method to manufacture them (2020-11-24),

13. 10391062 - Dry transglutaminase composition (2019-08-27),

14. 10179905 - Factor VII conjugates (2019-01-15),

15. 10138290 - Process for protein production (2018-11-27),

Novo Nordisk Healthcare AG is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on diabetes care, but also offers products in other therapeutic areas such as obesity, growth disorders, and hemophilia. Novo Nordisk is committed to discovering innovative solutions to improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

88 Patents

#15 in Zurich

#174 in Switzerland

#8,401 in the World

Zurich, Switzerland

Novo Nordisk Healthcare Ag

Forward Citations = 608

203 inventors:

Michael Bech Jensen (11 out of 11 patents)

Ole Hvilsted Olsen (10 out of 43 patents)

Egon Persson (10 out of 14 patents)

4. Janus Krarup (8 out of 8 patents)

5. Birthe Lykkegaard Hansen (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…